According to the Shiyao Innovation announcement, its holding subsidiary Jushi Biotech recently launched an open, multi-queue, multi-center phase II clinical trial evaluating SYS6041 combined medication to treat recurrent ovarian cancer. SYS6041 is an antibody-drug conjugate targeting folic acid receptor alpha. The phase II clinical trial of the combined use of this product was approved by the State Drug Administration in June 2026. Currently, the recruitment and screening of test subjects is being actively promoted. However, drug development is characterized by high investment, high risk, and long cycle times. There are risks such as failure to pass approval, etc., and there is no significant impact on performance in the short term.

According to the Shiyao Innovation announcement, its holding subsidiary Jushi Biotech recently launched an open, multi-queue, multi-center phase II clinical trial evaluating SYS6041 combined medication to treat recurrent ovarian cancer. SYS6041 is an antibody-drug conjugate targeting folic acid receptor alpha. The phase II clinical trial of the combined use of this product was approved by the State Drug Administration in June 2026. Currently, the recruitment and screening of test subjects is being actively promoted. However, drug development is characterized by high investment, high risk, and long cycle times. There are risks such as failure to pass approval, etc., and there is no significant impact on performance in the short term.